EU Fast-Track Review In Store For Takeda’s Dengue Vaccine
Accelerated Assessment Also For New Therapies From Regeneron And Bluebird Bio
Takeda will soon seek EU approval of its dengue vaccine candidate. The marketing application will be fast-tracked, as will the applications for Regeneron's evinacumab and bluebird bio's eli-cel Lenti-D gene therapy.
